KLOX Technologies Inc.: Two major deals signed

August 28th, 2014

Congratulations to KLOX Technologies Inc., a leading Canadian life sciences biopharmaceutical company which, represented by Gino Martel, a partner at BCF, has just signed two major deals. The first one is a worldwide license and joint venture agreement, excluding Canada, with LEO Pharma A/S to further develop and market KLOX Technologies’ biophotonic technology platform in dermatology, which includes a CE approved treatment for moderate to severe acne, as well as a subscription agreement whereby LEO Pharma acquired a minority interest in KLOX.

The second transaction is an exclusive supply, distribution and licensing agreement with Sandoz Canada for KLOX Technologies’ innovative and proprietary LumiCleanse™ System (also known as Lumigel Cleanse) for the treatment of acne vulgaris, and for its skin rejuvenation LumiBel™ System (also known as Fast & Mild Beauty System) in Canada.